Pluxee Shares Drop 3% Following JP Morgan's Target Reduction
Pluxee's stock experienced significant selling pressure this Wednesday at midday, falling by 3.15% to 10.45 euros in an otherwise upward-trending Parisian market. This recent downward trend occurs as JP Morgan has just lowered its price target on the stock. Over the past year, the employee benefits specialist has now declined by more than 52%.
On March 18th, American bank JP Morgan revised its price target on Pluxee downwards, reducing it from 18.00 euros to 15.50 euros, while maintaining a neutral recommendation on the stock. Despite this significant reduction of 13.9%, the new target suggests a potential rebound of approximately 48% compared to the current price of 10.45 euros.
This recalibration reflects the deteriorated trajectory of the stock in recent months. Pluxee has seen a decline of 21.6% over three months and 2.1% in just the last week, indicating a continuous erosion in valuation. The publication of the first half of 2026 results, expected on April 16th, will be a crucial moment to assess the operational dynamics of the group formed from the spin-off of Sodexo.
Technical Analysis: Pluxee Nears Support Threshold
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, today's drop brings Pluxee closer to its support level at 10.41 euros, now only four cents away. A downward breach of this zone could pave the way for a new phase of decline, in a context where the stock is significantly below its 50-day (11.32 euros) and 200-day (15.01 euros) moving averages. This substantial gap with the 200-day moving average, over 30%, illustrates the depth of the bearish trend on the stock.
The Relative Strength Index (RSI) stands at 47, an intermediate level that indicates neither an oversold condition nor a rebound dynamic. Pluxee moves contrary to the CAC 40, which is up by 0.89% in the session, and the SBF 120, which is up by 0.93%. For comparison, Capgemini is up by 0.43% and Sartorius Stedim Biotech is advancing by 1.49% at the same time, highlighting the isolation of the stock in today's session.
SectorTickets restaurants›Services de traitement des transactions
Context
Period
Period: 1T 2026
Guidance from the release
Trimestre après trimestre, nous enregistrons un démarrage solide de l’exercice 2026, porté par la dynamique commerciale de l'activité Avantages aux salariés; nous avons poursuivi notre feuille de route stratégique avec les acquisitions de Skipr et ProEves et restons confiants dans notre capacité à délivrer des performances durables malgré un environnement réglementaire exigeant au Brésil.
Démarrage robuste au T1 2026 : chiffre d'affaires total de 308 M€ (+9,0 % organique), solide croissance en Amérique latine, effet de change négatif (notamment livre turque) et impact réglementaire potentiel au Brésil; exécution active de la stratégie M&A.
Risks mentioned
Évolutions réglementaires au Brésil pouvant impacter les résultats (impact anticipé H1 2027 si confirmées)
Effets de change défavorables (dépréciation de la livre turque, impact sur croissance publiée)
Fin ou redimensionnement des programmes d'aide publique en Europe continentale
Report de commande d'un large programme en Roumanie affectant le timing du volume d'affaires
Opportunities identified
Pipeline M&A solide et diversifié permettant d'accroître l'offre multi-avantages
Croissance soutenue en Amérique latine, en particulier au Brésil
Renforcement de l'offre via les acquisitions de Skipr (mobilité) et ProEves (garde d'enfants) pour pénétrer de nouveaux segments
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
